Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.9K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.9K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.9K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.9K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

692
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
692
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

2.7K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.7K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

3.3K
The pathophysiology of pneumonia involves the following steps:
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idiopathic pulmonary fibrosis risk loci in East Asian populations mirror those of European populations.

American journal of respiratory and critical care medicine·2026
Same author

Artificial intelligence in idiopathic pulmonary fibrosis: advances, challenges and future directions.

The European respiratory journal·2025
Same author

Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis.

The European respiratory journal·2025
Same author

Matrix metalloprotease-7 is associated with post-COVID-19 persistent lung abnormalities.

ERJ open research·2024
Same author

Altered expression pattern of immune response-related genes and isoforms in hypersensitivity pneumonitis lung fibroblasts.

Scientific reports·2024
Same author

Determination of loss of chromosome Y in peripheral blood cells in males with idiopathic pulmonary fibrosis.

The European respiratory journal·2024

Related Experiment Video

Updated: Feb 20, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.1K

Idiopathic pulmonary fibrosis.

Fernando J Martinez1, Harold R Collard2, Annie Pardo3

  • 1Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York-Presbyterian Hospital/Weill Cornell Medical Center, 1305 York Avenue, Box 96, Room Y-1059, New York, New York 10021, USA.

Nature Reviews. Disease Primers
|October 21, 2017
PubMed
Summary

Idiopathic pulmonary fibrosis (IPF) is a progressive lung scarring disease affecting millions. New treatments like pirfenidone and nintedanib slow disease progression, and early detection via biomarkers is a key research focus.

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.9K
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.1K

Related Experiment Videos

Last Updated: Feb 20, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.1K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.9K
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.1K

Area of Science:

  • Pulmonology
  • Radiology
  • Genetics

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease causing scarring and impaired quality of life.
  • Affecting approximately 3 million people globally, IPF incidence rises with age.
  • Diagnosis involves excluding other interstitial lung diseases and identifying the usual interstitial pneumonia (UIP) pattern.

Purpose of the Study:

  • To summarize the current understanding of IPF diagnosis, pathogenesis, and management.
  • To highlight recent advancements in pharmacotherapy for IPF.
  • To discuss emerging strategies for early IPF detection.

Main Methods:

  • Review of diagnostic criteria for IPF, including high-resolution CT and lung biopsy.
  • Analysis of the proposed biological mechanisms underlying IPF pathogenesis.
  • Evaluation of the efficacy of pirfenidone and nintedanib in clinical management.

Main Results:

  • The UIP pattern on imaging is characterized by bilateral, peripheral, and basal reticular changes with traction bronchiectasis and cystic airspaces.
  • Pirfenidone and nintedanib have been shown to decrease physiological progression and improve progression-free survival in IPF patients.
  • Early identification of IPF is a critical goal, with research exploring combinations of biomarkers, demographics, and imaging data.

Conclusions:

  • IPF management has advanced with approved therapies slowing disease progression.
  • Further research is needed to fully elucidate IPF susceptibility and improve early diagnostic capabilities.
  • Combining biomarkers, demographics, and imaging holds promise for earlier IPF detection.